attana - sensor technologies

Malaria protein could be key in destroying 9 of 10 cancers

Attana customer CMP and group leader Prof. Ali Salanti presents groundbreaking cancer research.

Stockholm, October 15, 2015 – Research carried out by Professor Ali Salanti's group at The Centre for Medical Parasitology (CMP) at the University of Copenhagen/Rigshospitalet has been covered by the world press. The reason for the publicity is their research paper, "Targeting Human Cancer by a Glycosaminoglycan Binding Malaria Protein" which was recently published in Cancer Cell (©Elsevier Inc).

18 months ago Dr. Salanti's group received their second Attana system and at the time commented as follows, “We recently engaged Attana CRO services to verify cell assays, and the positive outcome led us to purchase an Attana Cell 200 system of our own.” The research partly enabled by their Attana Cell 200 system has now lead to a possible breakthrough in cancer therapy.

Attana congratulates Prof. Salanti and his team on their accomplishments to date and wish them continued success.

For more information about CMP visit

An abstract of the publication can be found here.

To read about the Attana-CMP cooperation click here

To learn more about Attana contract research services and our label free cell-based biosensors, please visit, or contact our sales department,

About Attana: Attana was founded in 2002 with the vision of in-vitro characterization of molecular interactions mimicking in-vivo conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera and cell-based assays. Attana’s products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. Attana Movie